Healthy volunteers help test new Infection-Fighting drug combo
NCT ID NCT06079775
First seen Nov 03, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This early-stage study tested a new oral drug combination (xeruborbactam prodrug plus ceftibuten) in 53 healthy adults aged 18 to 55. The main goal was to check safety, side effects, and how the drugs move through the body. No treatment was given for any illness; the study simply gathered important safety and dosing information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CMAX
Adelaide, South Australia, 5000, Australia
Conditions
Explore the condition pages connected to this study.